Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Quantitative phosphoproteomics by mass spectrometry: past, present, and future.
PMID 18846511 · PMC2701620 · Proteomics · 2008 · 8 claims · 6 setups
Selective enrichment of phosphopeptides (antiphosphotyrosine IP, IMAC, TiO2/MOAC, SCX, chemical tagging) is required to detect substoichiometric, transient phosphorylation events by MS
-
Full-text index only
Phosphoproteomics: unraveling the signaling web.
PMID 18922462 · PMC2754874 · Molecular cell · 2008 · 8 claims · 8 setups
Integrating discovery-based MS phosphoproteomics with targeted protein microarray technologies yields a more complete picture of signaling networks and improves clinical translation of findings.
-
Full-text index only
Transcriptomic Responses of the Marine Diatom Phaeodactylum tricornutum to High Carbon and Low Nitrogen Stress.
PMID 41522215 · PMC12789813 · Ecology and evolution · 2026 · 8 claims · 6 setups
Low nitrogen elicits a broader transcriptomic response than high CO2 (4267 vs. 2424 DEGs)
-
Full-text index only
Phosphoproteomics by mass spectrometry: insights, implications, applications and limitations.
PMID 19929607 · PMC2931417 · Expert review of proteomics · 2009 · 8 claims · 8 setups
Serine/threonine phosphorylation widely functions to modulate protein-protein interactions (PPIs) across signaling systems
-
Full-text index only
The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer.
PMID 40981426 · PMC12877753 · Cancer discovery · 2026 · 8 claims · 7 setups
FOLFIRI-resistant PDX tumors show transcriptional upregulation of innate immunity and mitochondrial metabolism genes and reduced expression of DNA polymerase POLD1
-
Full-text index only
Characterizing Response to PARP Inhibitor Treatment Combinations in Advanced Prostate Cancer.
PMID 42193276 · PMC13203762 · Biomedicines · 2026 · 8 claims · 8 setups
PARPi + ARPi combinations are effective in ARPi-sensitive (C4-2B) and ARPi-resistant (AbiR, MDVR) prostate cancer models, but provide the greatest benefit in ARPi-sensitive cells